The purpose of this report is to estimate diabetes prevalence and annual health care costs for people with diabetes in 1992, compare
We estimate that percapita annual health care expenditures in 1992 were more than three times greater for diabetics ($9,493 ) than for nondiabetics ($2,604) . Percapita expenditures for confirmed diabetics ($11,157) were more than four times greater than for nondiabetics.
In 1992, diabetics constituted 4.5% of the U.S. population but accounted for 14.6% of total U.S. health care expenditures ($105 billion). Confirmed diabetics constituted 3.1% of the U.S. population but accounted for 11.9% of total U.S. health care expenditures ($85 billion). This study found that health care expenditures for people with diabetes constituted about one in seven health care dollars spent in 1992. Health care reform and insurers should take note of these findings and structure benefit packages to promote care likely to reduce the costs of caring for diabetics. (J Clin Endocrinol Metab 78: 809A-809F, 1994) D IABETES mellitus is a chronic and potentially disabling disease which represents a major public health and clinical concern (l-3).
People with the disease are at increased risk of developing chronic complications related to ophthalmic, renal, neurological, cerebrovascular, cardiovascular, and peripheral vascular disease (4). Diabetics, for example, are more. likely than their nondiabetic peers to have heart attacks (5), strokes (6), amputations (7), kidney failure (ES), and blindness (9). As a result of the disease and its complications, people with diabetes have more frequent and intensive encounters with the health care system (1 O-l 2). The critical methodological question in estimating the costs of diabetes is the extent to which diabetes-related complications should be included.
The economic burden of diabetes has been previously estimated by studies applying conventional prevalence-based cost-of-illness techniques (13), which count only the health care expenditures (direct costs) and lost productivity (indirect costs) specifically attributable to diabetes. The cost of diabetes in 1984, for example, was estimated to be $14 billion, with direct medical care costs incurred as a result of diabetes ranging from $7. 4-12.0 billion (14) . This study excluded costs associated with complications 
Results
The prevalence of diabetes
We identified a total of 1620 diabetics in the NMES database. The majority (92.7% of identified diabetics) were identified because they answered "yes" to the NMES question, "Have you ever been told by a doctor that you have diabetes (high blood sugar)?" The remaining 118 diabetics were identified because they reported taking insulin or another diabetic drug or had a health care encounter specifically SPECIAL ARTICLE 809C related to diabetes as indicated by a diabetes-specific ICD-9-CM code. Estimates of diabetes prevalence by age are presented in Table 1 for dental costs. 
Comment
Using data on diabetes prevalence, health care use, and health care costs from the 1987 NMES, we have estimated that 14.6% percent of total health care expenditures were incurred by the 4.5% percent of the general population who had diabetes in 1992. We included in our estimate costs associated with inpatient hospital care, outpatient care, professional office visits, emergency room care, dental care, prescription drugs, home care, and, durable medical equipment. We found that diabetics, on average, incur health care costs 3.6-fold greater than those incurred by people without the disease. Confirmed diabetics incurred health care costs 4.28-fold greater than nondiabetics.
These findings are consistent with earlier research that average health care expenditures for diabetics were about three times greater than expenditures for nondiabetics (14) . Also consistent with previous research, 66% of expenditures of people with diabetes were incurred in inpatient settings (14) (15) (16) 20) .
As implied by the prevalence figures in Table 1 , diabetics Our diabetes prevalence rate of 45 per 1000 population, derived from the NMES, is higher than estimates in other national surveys. The 1991 National Health Interview Survey (NHIS) estimated diabetes prevalence at about 29 per 1000 population (28), whereas Harris et al. (29) estimated 1980 diabetes prevalence for those 20-74 yr of age at about 34 per 1000 population using the National Health and Nutrition Survey II. Like NMES, both the NHIS and National Health and Nutrition Survey II asked respondents whether they had ever been told by a physician that they have diabetes. The NMES survey, however, included the parenthetical phrase (high blood sugar) at the end of the question. Although inclusion of this phrase may have identified some additional diabetics, it also could have prompted some respondents to answer "yes" when they did not actually meet the clinical criteria for a diagnosis of diabetes (e.g. people with gestational diabetes or those informed by a physician that they have high blood sugar and are borderline diabetics). This may tend to overstate diabetes prevalence.
To obtain a more conservative estimate of prevalence and costs, we also calculated figures for only those diabetics whose diagnoses could be confirmed through rigorous validation criteria. The results were no less significant; although confirmed diabetics constituted only 3.1% of the population, they accounted for 11.9% of total health care expenditures, or approximately 1 in 8 U.S. health care dollars spent in 1992. Moreover, we would note that even this conservative estimate of diabetes prevalence is higher than estimates from the NHIS, which is commonly used to estimate the number of diagnosed diabetics in the U.S. population. Our conserv- ative estimate of 31 diagnosed diabetics per 1000 population probably represents a lower-bound estimate, with actual rates falling between 31-45 diabetics per 1000 population.
Our estimate of total health care expenditures for diabetics may understate actual costs for several reasons. First, we did not include costs associated with nursing home care. Previous research has estimated that nursing home costs specifically attributable to NIDDM were $3.44 billion in 1986 (15). Since the prevalence of nursing home stays for diabetics is greater than for nondiabetics (30), our estimate of total health care expenditures for diabetics could increase considerably if nursing home costs were included. We also did not estimate the indirect costs associated with diabetes such as forgone productivity due to disability and premature death. One study estimated that the indirect costs of both IDDM and NIDDM ($10.79 billion in 1987) actually exceeded direct costs ($9.6 billion in 1987) (1) (14), whereas another study estimated that indirect costs associated with NIDDM alone were $8.1 billion in 1986 (17). Finally, we did not estimate health care costs for undiagnosed diabetics. The number of undiagnosed diabetics may actually be as high as diagnosed diabetics (29). Although undiagnosed diabetics may not be expected to incur health care costs as high as diagnosed diabetics, costs might increase over time as the complications of diabetes necessitate more frequent and intensive health care interventions. the health care system could be realized if even a fraction of these costs could be avoided through prevention or effective management of the disease and its complications. Several recent studies have found that the onset of diabetes-related morbidity may be postponed through control of blood glucose levels (31, 32). Of particular potential import are findings from the Diabetes Control and Complications Trial (DCCT), a lo-yr, prospective, randomized clinical trial funded by the National Institutes of Health, which tested the effectiveness of intensive treatment in delaying the onset and progression of diabetes-related complications among 1441 insulin-dependent diabetics. Recently published findings report that tight control of blood glucose levels can delay the onset and slow the progression of retinopathy, nephropathy, and neuropathy among type I diabetics by as much as 70% compared with patients receiving conventional treatment (33). More research and analysis will undoubtedly be conducted to determine the extent to which DCCT results apply to non-insulin-dependent diabetics (who comprise approximately 90% of all diabetics), the risks associated with intensive control of blood glucose levels such as hypoglycemia, and the cost-effectiveness of the intensive interventions used in the DCCT. The American Diabetes Association recently stated its position that results from the DCCT likely apply to both insulin-dependent and non-insulin-dependent diabetics (34). This study confirms the previously undocumented belief Taken together, our findings on health care costs for that the health care costs for people with diabetes are stagdiabetics and recent findings on the clinical efficacy of mangering. Given the magnitude of current expenditures made aging diabetes have important policy implications. Policy on behalf of people with diabetes, these findings have immakers and insurers should be made aware of emerging portant implications for health policy. Significant savings to evidence on the effectiveness of interventions in reducing The entire submission should not exceed 10 double-spaced pages and should be in the format of a clinical pathological conference. The case or cases should be presented briefly with pertinent positive and negative information as well as relevant laboratory data. The laboratory data should be presented in SI units with the normal ranges noted in parentheses.
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